MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Pipeline Progress | Explore MoonLake's clear product development timeline, offering transparency and potential catalysts for growth in the competitive biopharmaceutical landscape |
Financial Challenges | Delve into MoonLake's financial health, balancing strong cash positions against projected losses and the implications for future growth and investor confidence |
Market Dynamics | Learn how MoonLake navigates a competitive market, with analyst price targets ranging from $65 to $104 amidst anticipated rival product launches |
Industry Potential | Discover the positive outlook for the biopharmaceutical sector, presenting opportunities for MoonLake to capitalize on unmet medical needs and technological advancements |
Metrics to compare | MLTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMLTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −24.1x | −4.7x | −0.5x | |
PEG Ratio | 0.12 | −0.03 | 0.00 | |
Price/Book | 8.6x | 2.1x | 2.6x | |
Price / LTM Sales | - | 9.0x | 3.2x | |
Upside (Analyst Target) | 34.6% | 178.3% | 40.5% | |
Fair Value Upside | Unlock | 5.4% | 4.4% | Unlock |